Increased sCD200 levels in vitreous of patients with proliferative diabetic retinopathy and its correlation with VEGF and proinflammatory cytokines

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 11, 2015, Pages 6565-6572

  Xu, Yue ^a   Cheng, Qiaochu ^a   Yang, Boyu ^a   Yu, Shanshan ^a   Xu, Fan ^a   Lu, Lin ^a   Liang, Xiaoling ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Proinflammatory cytokines; Proliferative diabetic retinopathy; SCD200; Vascular endothelial growth factor; Vitreous samples

Indexed keywords

CD200 RECEPTOR; CXCL9 CHEMOKINE; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANTIGENS, CD200; LEUKOCYTE ANTIGEN; VASCULOTROPIN A;

ADULT; ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DIABETIC MACULAR EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROLIFERATIVE DIABETIC RETINOPATHY; PROTEIN EXPRESSION; RETINA DETACHMENT; VITRECTOMY; VITREOUS BODY; AGED; BIOSYNTHESIS; DIABETIC RETINOPATHY; INFLAMMATION; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTIGENS, CD; CYTOKINES; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY; VITREOUS BODY;

EID: 84944206774     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.15-16854     Document Type: Article

References (35)

1. Abu El-Asrar AM, Mohammad G, Nawaz MI, Siddiquei MM. High-mobility group box-1 modulates the expression of inflammatory and angiogenic signaling pathways in diabetic retina. [published online ahead of print August 19, 2015]. Curr Eye Res. doi:10.3109/02713683.2014.982829.
2. Arden GB, Sivaprasad S. The pathogenesis of early retinal changes of diabetic retinopathy. Doc Ophthalmol Adv Ophthalmol. 2012;124:15-26.
3. Mahdy RA, Nada WM, Hadhoud KM, El-Tarhony SA. The role of vascular endothelial growth factor in the progression of diabetic vascular complications. Eye. 2010;24:1576-1584.
4. Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18:1450-1452.
5. Spijkerman AM, Gall MA, Tarnow L, et al. Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in Type 2 diabetes. Diabetic Med. 2007;24:969- 976.
6. van Hecke MV, Dekker JM, Nijpels G, et al. Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn Study. Diabetologia. 2005;48:1300-1306.
7. Wakabayashi Y, Usui Y, Okunuki Y, et al. Correlation of vascular endothelial growth factor with chemokines in the vitreous in diabetic retinopathy. Retina. 2010;30:339-344.
8. Keeley EC, Mehrad B, Strieter RM. Chemokines as mediators of tumor angiogenesis and neovascularization. Exp Cell Res. 2011;317:685-690.
9. Nawaz MI, Van Raemdonck K, Mohammad G, et al. Autocrine CCL2, CXCL4, CXCL9 and CXCL10 signal in retinal endothelial cells and are enhanced in diabetic retinopathy. Exp Eye Res. 2013;109:67-76.
10. Rijkers ES, de Ruiter T, Baridi A, Veninga H, Hoek RM, Meyaard L. The inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes. Mol Immunol. 2008;45: 1126-1135.
11. Barclay AN, Wright GJ, Brooke G, Brown MH. CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol. 2002;23:285-290.
12. Chen Z, Marsden PA, Gorczynski RM. Role of a distal enhancer in the transcriptional responsiveness of the human CD200 gene to interferon-gamma and tumor necrosis factor-alpha. Mol Immunol. 2009;46:1951-1963.
13. Simelyte E, Criado G, Essex D, Uger RA, Feldmann M, Williams RO. CD200-Fc, a novel antiarthritic biologic agent that targets proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis. Arthritis Rheum. 2008;58: 1038-1043.
14. Hoek RM, Ruuls SR, Murphy CA, et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science. 2000;290:1768-1771.
15. Dick AD, Carter D, Robertson M, et al. Control of myeloid activity during retinal inflammation. J Leukocyte Biol. 2003; 74:161-166.
16. Dick AD, Broderick C, Forrester JV, Wright GJ. Distribution of OX2 antigen and OX2 receptor within retina. Invest Ophthalmol Vis Sci. 2001;42:170-176.
17. Carter DA, Dick AD. CD200 maintains microglial potential to migrate in adult human retinal explant model. Curr Eye Res. 2004;28:427-436.
18. Schuetz E, Thanos S. Microglia-targeted pharmacotherapy in retinal neurodegenerative diseases. Curr Drug Targets. 2004; 5:619-627.
19. Singh A, Falk MK, Hviid TV, Sorensen TL. Increased expression of CD200 on circulating CD11bþ monocytes in patients with neovascular age-related macular degeneration. Ophthalmology. 2013;120:1029-1037.
20. Hernangomez M, Mestre L, Correa FG, et al. CD200-CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation. Glia. 2012;60: 1437-1450.
21. Lyons A, McQuillan K, Deighan BF, et al. Decreased neuronal CD200 expression in IL-4-deficient mice results in increased neuroinflammation in response to lipopolysaccharide. Brain Behav Immun. 2009;23:1020-1027.
22. Akman-Karakas A, Yalcin AD, Koc S, et al. There might be a role for CD200 in the pathogenesis of autoimmune and inflammatory skin disorders. Med Sci Monit. 2013;19:888- 891.
23. Yalcin AD, Genc GE, Celik B, Gumuslu S. Anti-IgE monoclonal antibody (omalizumab) is effective in treating bullous pemphigoid and its effects on soluble CD200. Clin Lab. 2014;60: 523-524.
24. Chakera A, Bennett SC, Morteau O, Bowness P, Luqmani RA, Cornall RJ. The phenotype of circulating follicular-helper T cells in patients with rheumatoid arthritis defines CD200 as a potential therapeutic target. Clin Dev Immunol. 2012;2012: 948218.
25. Taylor N, McConachie K, Calder C, et al. Enhanced tolerance to autoimmune uveitis in CD200-deficient mice correlates with a pronounced Th2 switch in response to antigen challenge. J Immunol. 2005;174:143-154.
26. Taylor S, Calder CJ, Albon J, Erichsen JT, Boulton ME, Morgan JE. Involvement of the CD200 receptor complex in microglia activation in experimental glaucoma. Exp Eye Res. 2011;92: 338-343.
27. Cai J, Boulton M. The pathogenesis of diabetic retinopathy: old concepts and new questions. Eye. 2002;16:242-260.
28. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Molec Biol. 2006;39:469-478.
29. Abu El-Asrar AM, Nawaz MI, Kangave D, Mairaj Siddiquei M, Geboes K. Angiogenic and vasculogenic factors in the vitreous from patients with proliferative diabetic retinopathy. J Diabetes Res. 2013;2013:539658.
30. Abu El-Asrar AM, Nawaz MI, Kangave D, Siddiquei MM, Ola MS, Opdenakker G. Angiogenesis regulatory factors in the vitreous from patients with proliferative diabetic retinopathy. Acta Diabetol. 2013;50:545-551.
31. Boyer DS, Hopkins JJ, Sorof J, Ehrlich JS. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab. 2013;4:151-169.
32. Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012;119:1658-1665.
33. Stratton IM, Aldington SJ, Taylor DJ, Adler AI, Scanlon PH. A simple risk stratification for time to development of sightthreatening diabetic retinopathy. Diabetes Care. 2013;36:580- 585.
34. Das UN. Lipoxins, resolvins, and protectins in the prevention and treatment of diabetic macular edema and retinopathy. Nutrition. 2013;29:1-7.
35. Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol. 2002;133:70-77.